Amneal Pharmaceuticals - AMRX Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings or view top-rated stocks.

1 analysts have issued 1-year price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price forecasts range from $4.00 to $7.00. On average, they anticipate the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 118.3% from the stock's current price.
View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts.

Amneal Pharmaceuticals' stock was trading at $1.99 at the beginning of the year. Since then, AMRX stock has increased by 26.6% and is now trading at $2.52.
View the best growth stocks for 2023 here.

Amneal Pharmaceuticals saw a increase in short interest in the month of December. As of December 30th, there was short interest totaling 7,740,000 shares, an increase of 142.6% from the December 15th total of 3,190,000 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 6.8 days. Currently, 7.8% of the company's stock are short sold.
View Amneal Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our AMRX earnings forecast.

Amneal Pharmaceuticals will be holding an earnings conference call on Thursday, March 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 866-813-9403 with passcode "942331".

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.01. The business had revenue of $528.30 million for the quarter, compared to analysts' expectations of $544.08 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 57.89% and a negative net margin of 6.17%. Amneal Pharmaceuticals's revenue for the quarter was up 1.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.16 earnings per share.

Amneal Pharmaceuticals updated its FY22 earnings guidance on Tuesday, January, 10th. The company provided earnings per share (EPS) guidance of $0.65-0.70 for the period, compared to the consensus earnings per share estimate of $0.66. The company issued revenue guidance of $2.15-2.25 billion, compared to the consensus revenue estimate of $2.18 billion.

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Amneal Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.52%), Strs Ohio (0.07%), Los Angeles Capital Management LLC (0.06%), Assenagon Asset Management S.A. (0.02%), Hennion & Walsh Asset Management Inc. (0.02%) and Hedges Asset Management LLC (0.02%). Insiders that own company stock include Chintu Patel, Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco, Nikita Shah, Paul M Meister and Tpg Gp A, Llc.
View institutional ownership trends.

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRX stock can currently be purchased for approximately $2.52.

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $765.05 million and generates $2.09 billion in revenue each year. The company earns $10.62 million in net income (profit) each year or ($0.87) on an earnings per share basis.

The company employs 7,000 workers across the globe.

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.